CD274 and neoplasm: Recent studies have consistently revealed biomarkers such as tumor mutation burden (TMB), neoantigen load (NAL), programmed cell-death receptor 1 ligand (PD-L1) expression, and lactate dehydrogenase (LDH) to predict therapeutic benefit in SKCM (Jiang J et al., 2020).